Efficacy and safety of eribulin therapy for breast cancer with liver metastasis: a retrospective real-world study
Frontiers in Oncology · 12.05.2026 · 16
DOI: 10.3389/fonc.2026.1795498 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 12.05.2026. Verfasst von Zishuo Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Eribulin is a microtubule inhibitor indicated for metastatic breast cancer (MBC). Previous studies have demonstrated its overall survival benefit in patients with MBC, but data on its efficacy in those with liver metastases are lacking.
Methods
We retrospectively analyzed the efficacy and safety of eribulin in 73 patients with liver metastases from breast cancer treated at the First Affiliated Hospital of Zhengzhou University between 2020 and 2024. Systemic progression-free survival and objective response rate were assessed per RECIST version 1.1, and adverse events were evaluated.
Results
The median progression-free survival was 3.7 months (95% CI: 2.8–4.6), with a systemic objective response rate of 15.1% (95% CI: 7.8%–25.4%; partial responses only). The highest objective response rate (21.2%) was numerically observed in the HR+/HER2− subtype. The most common adverse events were neutropenia (42.5%), fatigue (37.0%), alopecia (34.2%), and peripheral neuropathy (28.8%), with no treatment-related deaths.
Conclusions
In this single-center retrospective exploratory analysis, eribulin-based therapy demonstrated preliminary activity in heavily pre-treated breast cancer patients with liver metastases. These hypothesis-generating findings warrant further prospective validation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zitieren
APA
Wang, Z., Xu, X., Lv, P., & Zhang, J. (2026). Efficacy and safety of eribulin therapy for breast cancer with liver metastasis: a retrospective real-world study. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1795498
Vancouver
Wang Z, Xu X, Lv P, Zhang J. Efficacy and safety of eribulin therapy for breast cancer with liver metastasis: a retrospective real-world study. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1795498
BibTeX
@article{Wang2026,
author = {Wang, Zishuo and Xu, Xiaodong and Lv, Pengwei and Zhang, Jianxiang},
title = {Efficacy and safety of eribulin therapy for breast cancer with liver metastasis: a retrospective real-world study},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1795498}
}
EUVIMED